Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb UFT

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA issues "not approvable" letter for the combination of uracil and tegafur March 23. The NDA, which was seeking approval of UFT for use with leucovorin in the treatment of advanced colorectal cancer, originally was submitted in February 1999 and was resubmitted April 20, 2000. BMS says it will consider "all available options to obtain approval of UFT in the U.S.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel